- Home
- AVIR vs ABEO Comparison
AVIR vs ABEO Comparison
Compare AVIR & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | ABEO |
|---|---|---|
| Founded | 2012 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.9M | 280.2M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AVIR | ABEO |
|---|---|---|
| Price | $5.65 | $4.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.00 | ★ $20.00 |
| AVG Volume (30 Days) | 571.5K | ★ 1.4M |
| Earning Date | 03-05-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.00 | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | ★ $351,367,000.00 | $2,998,000.00 |
| Revenue This Year | N/A | $1,276.65 |
| Revenue Next Year | N/A | $112.53 |
| P/E Ratio | ★ N/A | $4.44 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $2.46 | $3.93 |
| 52 Week High | $6.45 | $7.54 |
Technical Indicators
Market Signals| Indicator | AVIR | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 46.02 |
| Support Level | $3.33 | $4.53 |
| Resistance Level | $6.45 | $5.62 |
| Average True Range (ATR) | 0.27 | 0.19 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 56.47 | 44.30 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.